牛牛AI助理已提取核心訊息
TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, has successfully regained compliance with the Nasdaq minimum bid price requirement, as confirmed on January 2, 2024. The company had previously been notified by Nasdaq on June 22, 2023, that it did not meet the minimum bid price of $1.00 for 30 consecutive business days. To address this, TC BioPharm was required to maintain a closing bid price of at least $1.00 for 10 consecutive business days. This condition was fulfilled on December 29, 2023, leading to the company's compliance with Nasdaq Listing Rule 5550(a)(2). The company issued a press release on January 4, 2024, to announce the regained compliance. TC BioPharm focuses on developing allogeneic gamma-delta T cell therapies for cancer treatment and is conducting clinical trials for its product line, including a Phase 2b/3 pivotal trial for OmnImmune® in the treatment of acute myeloid leukemia.
TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, has successfully regained compliance with the Nasdaq minimum bid price requirement, as confirmed on January 2, 2024. The company had previously been notified by Nasdaq on June 22, 2023, that it did not meet the minimum bid price of $1.00 for 30 consecutive business days. To address this, TC BioPharm was required to maintain a closing bid price of at least $1.00 for 10 consecutive business days. This condition was fulfilled on December 29, 2023, leading to the company's compliance with Nasdaq Listing Rule 5550(a)(2). The company issued a press release on January 4, 2024, to announce the regained compliance. TC BioPharm focuses on developing allogeneic gamma-delta T cell therapies for cancer treatment and is conducting clinical trials for its product line, including a Phase 2b/3 pivotal trial for OmnImmune® in the treatment of acute myeloid leukemia.
正如2024年1月2日確認的那樣，臨床階段的生物技術公司TC Biopharm（Holdings）PLC已成功恢復對納斯達克最低出價要求的遵守。納斯達克此前曾於2023年6月22日通知該公司，該公司連續30個工作日未達到1.00美元的最低出價。爲了解決這個問題，TC BioPharm必須連續10個工作日將收盤價維持在至少1.00美元。該條件已於2023年12月29日得到滿足，這使該公司遵守了納斯達克上市規則5550（a）（2）。該公司於2024年1月4日發佈新聞稿，宣佈恢復合規。TC BioPharm專注於開發用於癌症治療的異基因伽瑪-德爾塔T細胞療法，並正在對其產品線進行臨床試驗，包括一項用於治療急性髓系白血病的OmnImmune® 的2b/3期關鍵試驗。
正如2024年1月2日確認的那樣，臨床階段的生物技術公司TC Biopharm（Holdings）PLC已成功恢復對納斯達克最低出價要求的遵守。納斯達克此前曾於2023年6月22日通知該公司，該公司連續30個工作日未達到1.00美元的最低出價。爲了解決這個問題，TC BioPharm必須連續10個工作日將收盤價維持在至少1.00美元。該條件已於2023年12月29日得到滿足，這使該公司遵守了納斯達克上市規則5550（a）（2）。該公司於2024年1月4日發佈新聞稿，宣佈恢復合規。TC BioPharm專注於開發用於癌症治療的異基因伽瑪-德爾塔T細胞療法，並正在對其產品線進行臨床試驗，包括一項用於治療急性髓系白血病的OmnImmune® 的2b/3期關鍵試驗。
有用
沒用